Epidermal growth factor receptor tyrosine kinase inhibitors and bone metastases: Different mechanisms of action for a novel therapeutic application?

Endocrine-Related Cancer

Volumn 13, Issue 1, 2006, Pages 3-6

  Normanno, Nicola ^a   Gullick, William J ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b UNIVERSITY OF KENT   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; GEFITINIB; GELATINASE B; PACLITAXEL; UROKINASE; VASCULOTROPIN;

ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; BONE MARROW CELL; BONE METASTASIS; CANCER CELL; CANCER INHIBITION; CANCER INVASION; CELL ACTIVATION; CELL DIFFERENTIATION; CELL INVASION; CELL PROLIFERATION; CELL SURVIVAL; DISEASE COURSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; OSTEOCLAST; PROSTATE CANCER; REVIEW;

ANTINEOPLASTIC AGENTS; BONE NEOPLASMS; HUMANS; MALE; PROSTATIC NEOPLASMS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 33645996708     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.01185     Document Type: Review

References (24)

1. Albain KS, Elledge R, Gradishar WJ, Hayes DF, Rowinsky E, Hudis C, Pusztai L, Tripathy D, Modi S & Rubi S 2002 Open-label, phase II, multicenter trial of ZD1839 ('Iressa') in patients with advanced breast cancer. Breast Cancer Research and Treatment 76 S33 (Abstract).
2. Angelucci A, Gravina GL, Rucci N, Millimaggi D, Festuccia C, Muzi P, Teti A, Vicentini C & Bologna M 2006 Suppression of EGF-R signalling reduces the incidence of prostate cancer metastasis in nude mice. Endocrine-Related Cancer 13 197-210.
3. Boyle WJ, Simonet WS & Lacey DL 2003 Osteoclast differentiation and activation. Nature 423 337-342.
4. Chan SK, Gullick WJ & Hill ME 2006 Mutations of the epidermal growth factor receptor in non-small cell lung cancer - Search and destroy. European Journal of Cancer 42 17-23.
5. Clark BR & Keating A 1995 Biology of bone marrow stroma. Annals of the New York Academy of Sciences 770 70-78.
6. Deans RJ & Moseley AB 2000 Mesenchymal stem cells: biology and potential clinical use. Experimental Hematology 28 875-884.
7. Guise TA & Mundy GR 1998 Cancer and bone. Endocrine Reviews 19 18-54.
8. Hirata A, Ogawa S, Kometani T, Kuwano T, Naito S, Kuwano M & Ono M 2002 ZD1839 (Iressa) induces antiangiogenic effects through inhibition of epidermal growth factor receptor tyrosine kinase. Cancer Research 62 2554-2560.
9. Huang SM, Li J & Harari PM 2002 Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Molecular Cancer Therapeutics 1 507-514.
10. Kim SJ, Uehara H, Karashima T, Shepherd DL, Killion JJ & Fidler IJ 2003 Blockade of epidermal growth factor receptor signaling in tumour cells and tumour-associated endothelial cells for therapy of androgen-independent human prostate cancer growing in the bone of nude mice. Clinical Cancer Research 9 1200-1210.
11. Leverton KE & Gullick WJ 2000 The type 1 family of growth factor receptors and their ligands in prostate cancer. In 'Endocrine Oncology' (ed S Ethier) Humana Press Inc, New Jersey, USA, 277-291.
12. Mbalaviele G, Jaiswal N, Meng A, Cheng L, Van De Bos C & Thiede M 1999 Human mesenchymal stem cells promote human osteoclast differentiation from CD34+ bone marrow hematopoietic progenitors. Endocrinology 140 3736-3743.
13. von Minckwitz G, Jonat W, Beckmann M, De Bois A, Kleeberg U, Kuhnie H, Kettner E, Hilfrich J, Torode J & Schneeweiss A 2003 A multicenter phase II trial to evaluate Gefitinib ('Iressa', ZD1839) (500 mg/day) in patient with metastatic breast cancer after previous chemotherapy treatment. European Journal of Cancer Supplements 1 S133.
14. Nemeth JA, Yousif R, Herzog M, Che M, Upadhyay J, Shekarriz B, Bhagat S, Mullins C, Fridman R & Cher ML 2002 Matrix metalloproteinase activity, bone matrix turnover, and tumour cell proliferation in prostate cancer bone metastasis. Journal of the National Cancer Institute 94 17-25.
15. Niida S, Kaku M, Amano H, Yoshida H, Kataoka H, Nishikawa S, Tanne K, Maeda N, Nishikawa S & Kodama H 1999 Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. Journal of Experimental Medicine 190 293-298.
16. Normanno N, Bianco C, De Luca A, Maiello MR & Salomon DS 2003 Target-based agents against ErbB receptors and their ligands: a novel approach to cancer treatment. Endocrine-Related Cancer 10 1-22.
17. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo F, Caponigro F & Salomon DS 2005a Epidermal growth factor receptor (EGFR) signaling in cancer. Gene, Epub ahead of print.
18. Normanno N, De Luca A, Aldinucci D, Maiello MR, Mancino M, D'Antonio A, De Filippi R & Pinto A 2005b Gefitinib inhibits the ability of human bone marrow stromal cells to induce osteoclast differentiation: implications for the pathogenesis and treatment of bone metastasis. Endocrine-Related Cancer 12 471-482.
19. Roodman GD 2001 Biology of osteoclast activation in cancer. Journal of Clinical Oncology 19 3562-3571.
20. Salomon DS, Brandt R, Ciardiello F & Normanno N 1995 Epidermal growth factor-related peptides and their receptors in human malignancies. Critical Reviews in Oncology and Hematology 19 183-232.
21. Takahashi N, Akatsu T, Udagawa N, Sasaki T, Yamaguchi A, Moseley JM, Martin TJ & Suda T 1988 Osteoblastic cells are involved in osteoclast formation. Endocrinology 123 2600-2602.
22. Udagawa N, Takahashi N, Akatsu T, Sasaki T, Yamaguchi A, Kodama H, Martin TJ & Suda T 1989 The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells. Endocrinology 125 1805-1813.
23. Weber KL, Doucet M, Price JE, Baker C, Kim SJ & Fidler IJ 2003 Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Research 63 2940-2947.
24. Younes MN, Yigitbasi OG, Park YW, Kim SJ, Jasser SA, Hawthorne VS, Yazici YD, Mandal M, Bekele BN, Bucana CD, Fidler IJ & Myers JN 2005 Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation. Cancer Research 65 4716-4727.